Targeting unmet clinical needs of 46 million patients living with chronic non-healing wounds worldwide, this platform develops first-in-class active repair small-molecule innovative drugs for refractory wounds such as diabetic foot ulcers, pressure injuries, venous ulcers and skin mucosal erosions. Unlike conventional passive wound care solutions, our core pipeline develops small-molecule drugs that activate endogenous tissue repair pathways. The full-chain technology integrates target discovery, natural product modification, AI druggability optimization and in vitro & in vivo wound repair evaluation, delivering fast-acting novel drugs that shorten healing cycles and lower amputation risks, tapping into the blue-ocean market of high-end wound care valued at over USD 10 billion. Currently, we hold a total of 20 patents related to wound healing drugs, including both granted patents and patents under examination.
Core Technical Modules
1. Wound Repair Target Identification & Verification Module
Using CRISPR reporter systems, protein microarrays and multi-pathway cytokine detection, we screen novel repair targets regulating epithelial regeneration, granulation tissue formation and inflammatory microenvironment remodeling. We also built in vitro functional evaluation systems for keratinocytes and fibroblasts to rapidly verify compounds’ activity in boosting cell proliferation, migration and anti-inflammation.
2. Dual-Source Lead Compound Development Module
We maintain two parallel molecular libraries: fully synthetic small molecules and modified natural products:
- Synthetic series: Benzamide and naphthalenone derivatives (Z15-3-19, EH-P002A, EH-P007U) featuring high bioavailability and strong target selectivity.
- Natural product series: Rutaecarpine-based TS-series compounds (TS-0296, TS-2790) with excellent safety profiles; AI structural modification drastically improves their wound-healing efficacy.
3. AI Intelligent Molecular Optimization & ADMET Evaluation Module
AI algorithms conduct targeted structural modification to optimize water solubility, skin permeability and metabolic stability, pre-empting in vivo toxicity risks. Comprehensive absorption, distribution, metabolism and excretion (ADME) druggability evaluations shorten lead optimization cycles and reduce clinical failure risks. Independent invention patents are filed for all AI-modified derivatives.
4. Standardized In Vivo Pharmacodynamic Evaluation Module for Chronic Wounds
We independently established multiple animal wound models including diabetic foot ulcers, pressure ulcers and surgical skin incisions. These models quantify wound closure rate, granulation tissue thickness, epithelialization degree and local inflammatory cytokine levels to compare therapeutic efficacy between test drugs and traditional dressings/topical formulations. The platform conducts complete local administration and systemic safety evaluations to support both topical and oral formulation development.
Core Platform Advantages
1. Outstanding Clinical Value: Moving beyond infection prevention limited to traditional wound care, our drugs actively activate endogenous repair pathways to drastically shorten healing cycles of chronic ulcers and reduce diabetic foot amputation risks, with clear clinical demand and high potential for inclusion in medical insurance and clinical guidelines.
2. Tiered Safety Profiles: Natural product derivatives are low-toxic and low-irritant for long-term topical skin use; synthetic compounds deliver stronger activity for severe refractory ulcers, forming a differentiated product portfolio.
3. Friendly Commercialization Threshold: Wound drug regulation offers favorable market access with shorter launch timelines and stable market demand.
4. Diversified Monetization Pathways: Early-stage lead compounds are available for licensing transfer; 80% patent equity can be transferred post-IND filing, alongside opportunities for joint development and formulation cooperation.
Platform Pipeline Outputs
The platform advances multiple preclinical R&D pipelines: TS-0296, Z15-3-19, EH-P002A (TM-A), and EH-P007U (U9). All candidates are undergoing simultaneous safety and in vivo pharmacodynamic validation. Core products are projected to launch commercially in 2033 with peak annual sales of USD 1–2 billion, delivering long-term stable cash flow to the company.
